Brief: Sab Bio Announces Positive Confirmatory Clinical Results
17/12/2025 13:08
Dec 17 (Reuters) - SAB Biotherapeutics Inc SABS.O: SAB BIO ANNOUNCES POSITIVE CONFIRMATORY CLINICAL RESULTS FROM THE PHASE 1 STUDY OF SAB-142 IN DEVELOPMENT FOR THE TREATMENT OF STAGE 3 T1D SAB BIOTHERAPEUTICS INC - SAB-142 WELL-TOLERATED, SUPERIOR SAFETY PROFILE TO RATG SAB BIOTHERAPEUTICS INC - PHASE 1 DATA CONFIRMS SAB-142 DOES NOT CAUSE SERUM SICKNESS Source text: ID:nGNX8c9hj0 Further company coverage: SABS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies